Nanoparticles for brain disease: translational failures, blood-brain barrier heterogeneity, and precision design constraints

Arun Kumar Nirmal; Haripriya Dayalan; Rohith S; Gayathri Ayyar

doi:10.33218/001c.157822

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

prnano

Articles
For Authors
Editorial Board
About
Issues
Blog
The Rising Talents List
Journal Policies

search
Facebook (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:46183/feed

ISSN 2639-9431

Review

Vol. 9, Issue 1, 2026

February 19, 2026 EDT

Nanoparticles for brain disease: translational failures, blood-brain barrier heterogeneity, and precision design constraints

Arun Kumar Nirmal, Btech, Mtech (candidate), Haripriya Dayalan, Ph.D, Rohith S, Btech, Mtech (candidate), Gayathri Ayyar, Btech (candidate),

Nanoparticlesblood–brain barrierbrain-related diseasesnanomedicinetargeted drug deliverytheranosticsbiomimetic nanoparticlesclinical translation

ccby-nc-4.0

• https://doi.org/10.33218/001c.157822

Photo by Shawn Day on Unsplash

prnano

Nirmal AK, Dayalan H, S R, Ayyar G. Nanoparticles for brain disease: translational failures, blood-brain barrier heterogeneity, and precision design constraints. Precis Nanomed. 2026;9(1):1748-1770. doi:10.33218/001c.157822

View more stats